BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options to purchase an aggregate of 80,700 shares, and restricted stock units covering an aggregate of 38,600 shares, of BioCryst common stock.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a corporate update.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2023.

MaxCyte, Inc. announced Company management will participate at two upcoming investor conferences.

Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on Monday, November 13, 2023.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its third quarter ended September 30, 2023.

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) today announced a new strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd (“Celest”), a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China.

FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company’s recent developments.